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Background: A recent study showed low adherence to the published treatment 
guidelines for axial spondyloarthritis (axSpA) / ankylosing spondylitis (AS). The aim of 
this study was to determine barriers to guideline adoption that are specific to axSpA / AS. 
Methods: A systematic literature review was conducted to learn which general barriers to 
guideline adoption have been proposed in the literature. A second systematic literature 
review was conducted to identify strategies to increase response rates in the deployment 
of electronic surveys. A survey was developed based on the findings from the literature, 
aimed to interrogate the perspective of rheumatologists on barriers within their practice. 
A focus group was conducted to gain insight from experts in the field. 
Results: The SLR identified 22 primary research articles on barriers to guideline 
adherence in axSpA / AS, almost all of which focused on drug therapy or physical 
therapy / exercise. Only 1 of the 22 studies was conducted in the US. The SLR on survey 
deployment methods identified 52 articles, 40 of which included sufficient information to 
calculate response rates. The mean response rate for online surveys distributed to 
rheumatologists was 0.33 with no statistically significant differences between surveys 
that contacted physicians once, twice or three or more times. From the literature, a 
framework was synthesized that captures relevant barriers to guideline adherence in 5 
categories: guideline factors, health professional factors, patient factors, practice setting 
 
 v 
factors and societal factors. A survey was drafted, with questions targeting each of the 
five categories included in the framework. Suggestions from the experts participating in 
the focus group resulted in a revised survey consisting of 33 questions. Additionally, the 
focus group proposed ideas for survey dissemination, including strong support for the 
utilization of social media in addition to email invitations.  
Conclusion: The literature on barriers to guideline adherence in axSpA / AS is limited, in 
particular in the domains of disease activity monitoring, osteoporosis screening / 
monitoring, and other non-pharmacologic therapies. Only a single US study on barriers to 
guideline adherence in axSpA / AS was identified, indicating the need for more research 
in this field. The focus group provided firsthand perspective, allowing for modification of 
the survey to capture the most informative data. The focus group also provided insight 
into survey dissemination methods and ideas to maximize participation. The SLR on 
electronic survey deployment suggests an expected response rate of 0.33 for surveys 
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Axial spondyloarthritis (axSpA) is an inflammatory disease predominantly affecting the 
spine and sacroiliac joint that includes radiographic and non-radiographic forms. The 
radiographic form is also known as ankylosing spondylitis (AS) and is detectable by X-
ray scans of the sacroiliac joints and / or the spine. AS is characterized by vertebral 
inflammation, which may lead to bone growth and fusion, detectable by X-ray scans of 
the sacroiliac joints and / or the spine.1 Axial spondyloarthritis has been found to mainly 
affect tissues that are exposed to mechanical strain, such as the sacroiliac joints, the spine 
and the entheses.2 As disease progresses, the non-radiographic form may transition into 
the radiographic form, as sequelae of sacroiliitis become noticeable on radiographs, 
though this is not the case for all patients. There is a strong genetic link between HLA-
B27 and axSpA, and while the exact mechanism is still unclear, HLA-B27 positivity is 
found in significantly higher prevalence in patients with AS compared with the general 
population.1 In fact, 80-90% of patients with AS are HLA-B27 positive compared to 8–
10% of the total white population.1 HLA-B27 status is also associated with disease 
severity as it pertains to structural damage to the joints and spine.1 According to Sieper 
and Poddubnyy, prevalence estimates for axSpA range from 0.32% to 1.4%” across 





Figure 1. Radiographic Sacroiliitis in Ankylosing Spondylitis. Radiograph of the pelvis showing fusion 
(ankylosis) of the sacroiliac joints characteristic of ankylosing spondylitis.3  
 
 
Treatment Recommendations for axSpA / AS 
In 2016, the American College of Rheumatology (ACR), the Spondylitis Association of 
America (SAA), and the Spondyloarthritis Research and Treatment Network 
(SPARTAN) published evidence-based treatment recommendations for patients with AS 
and non-radiographic axSpA.4 In 2019, the guidelines were updated in response to newly 
available medications, which caused reexamination of several recommendations, as well 
as some additions.5 According to the ACR / SAA / SPARTAN guidelines, the goal of 
therapy is to “alleviate symptoms, improve functioning, maintain the ability to work, 




Pharmacotherapy is a major focus of the recommendations. Forty-one of the eighty-six 
specific recommendations focus on pharmacologic treatment, providing guidance on the 
use of non-steroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) and 
IL-17A inhibitors, glucocorticoids, tofacitinib, sulfasalazine, and methotrexate. In the 
guideline publication, Ward et al. further discuss the management of comorbidities, as 
well as recommendations for physical therapy (PT) and back exercises in patients with 
both active and stable disease status. A section of the guidelines is dedicated to 
recommendations for measuring disease activity as well as screening recommendations 
for osteopenia / osteoporosis.5  
 
Adherence to Non-Pharmacologic Treatment Recommendations for axSpA / AS 
The following non-pharmacological management recommendations are taken from the 
2019 updated ACR / SAA / SPARTAN guidelines, and are identical to the 2016 
guidelines5: 
“20. We strongly recommend treatment with physical therapy over no treatment with 
physical therapy.” 
“31. We conditionally recommend advising unsupervised back exercises.” 
“42. We conditionally recommend the regular-interval use and monitoring of a validated 
AS disease activity measure.” 
“43. We conditionally recommend regular-interval use and monitoring of CRP 
concentrations or ESR over usual care without regular CRP or ESR monitoring.” 
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“45. We conditionally recommend screening for osteopenia / osteoporosis with DXA 
scan over no screening.” 
Recently, Patel et al. conducted a retrospective review of medical records at Partners 
HealthCare, which focused on adherence to the recommendations for disease activity 
monitoring, PT and osteoporosis screening in adults with AS.6 Partners HealthCare is a 
large hospital network in the Boston metropolitan area that includes Brigham and 
Women’s Hospital and Massachusetts General Hospital. Medical records were accessed 
via Partners HealthCare Epic electronic medical records (EMR) system. In order to be 
included, patients had to have 3 ICD-9 or 10 codes for AS, an imaging confirmed 
diagnosis of AS, and at least one rheumatology clinic visit for AS between July 2016 and 
June 2019. 304 patients met these inclusion criteria, and 564 visits were analyzed. Patel 
et al. discovered a low frequency of adherence to the ACR / SAA / SPARTAN 
recommendations for disease activity monitoring, PT and osteoporosis screening.6 They 
found that a clinical disease activity measure was recorded at 95 / 564 (16.9%) visits, an 
inflammatory marker blood test (CRP and / or ESR) was ordered at 294 / 564 (52.1%) 
visits. Evidence of completed, on-going, recommended, or prescribed PT for AS could be 
found in the records for 50 / 564 (8.9%) visits, while home back exercises were discussed 
or recommended at 42 / 564 (7.4%) visits. 58 / 304 (19.1%) patients had a DXA scan(s) 
at any time prior to June 30, 2019. The current study is a follow-up to Patel et al. to begin 
understand the barriers to implementation of AS treatment guidelines in clinical practice. 
 
General Barriers to Clinical Guideline Adherence 
 
5 
Many studies have looked at guideline adherence in general, from a non-disease specific 
standpoint. In fact, several studies have developed frameworks which aim to capture and 
classify the different barriers encountered in clinical practice.  
Cabana et al.7 performed a systematic literature review extracting data from 76 articles, 
after initially screening 5658 articles7. They identified 3 major groups of barriers which 
they categorized as pertaining to knowledge, attitude or behavior. Knowledge barriers 
include physician lack of awareness of or familiarity with the guidelines. Attitude barriers 
include physician lack of agreement, either with the guidelines as a whole or with 
specific aspects of the guidelines. Also included in this category is a lack of outcome 
expectancy by the physician, i.e., the idea that following the guideline will not have an 
impact on disease outcomes, as well as lack of motivation for the physician to comply 
with new guidelines, which may in part be due to the comfort with the current practice in 
place. Lastly, a lack of self-efficacy on the part of the physician is also considered an 
attitude barrier. Behavioral barriers include patient factors, which include, but are not 
limited to issues related to patient motivation, patient comorbidities, and patient 
preferences. Other behavioral barriers include guideline factors, such as lack of feasibility 
or applicability of guidelines in clinical practice. Additionally, environmental factors, 
such as practice setting and time constraints during visits are considered behavioral 
barriers. Cabana et al. presented this framework as a flow-chart, which we adapted into a 





Table 1. Barriers to Physician Adherence to Clinical Practice Guidelines. Adapted from Cabana et al.7 
Knowledge Attitude Behavior 
• Lack of Awareness 
• Lack of Familiarity 
• Lack of Agreement with Specific 
Guidelines 
• Lack of Agreement with General 
Guidelines 
• Lack of Outcome Expectancy 
• Lack of Self-Efficacy 
• Lack of Motivation / Inertia of Previous 
Practice  
• Patient Factors 
• Guideline Factors 
• Environmental Factors 
 
 
The systematic meta-review conducted by Francke et al.8, presents a framework that was 
derived from the analysis of twelve systematic reviews8. In their framework, Francke et 
al. defined 5 categories of barriers. The first, characteristics of the guidelines, includes 
issues with complexity as well as ease of implementation. The second category deals with 
characteristics of the implementation strategies. The third category is characteristics of 
the professionals, which encompasses barriers related to the physician’s knowledge and 
familiarity of the guidelines, as well as factors such as experience which may affect their 
ability to effectively apply the guidelines. The fourth category, characteristics of the 
patients, includes barriers related to patient motivation, or patient comorbidities. Lastly, 
the fifth category describes characteristics of the environment, with barriers such as 
insufficient staffing, increased costs, and lack of time. Unlike Cabana et al., Francke et al. 
included factors that facilitate implementation of the guidelines as well as factors that 
discourage implementation for each category. Initially presented as a bulleted list, the 





Table 2. Factors Influencing the Implementation of Clinical Guidelines for Healthcare Professionals. 
Adapted from Francke et al.8 
  Facilitates implementation Discourages implementation  
Characteristics of 
the guidelines 
• Easy to understand 
• Easy to try out in practice 
• Do not require specific 
resources 
• Complexity 




• Multi-faceted strategies  
• Comprehensive (greater variety 
and breadth) 
• Strategies requiring active 
professional participation 
• Single intervention strategy  
Characteristics of 
professionals 
• Less experience leads to 
increased likelihood of 
following guidelines 
• Lack of awareness of guidelines 
• Lack of familiarity with guidelines 
• Lack of agreement with guidelines 
Characteristics of 
patients 
 • Resistance to guidelines 
• May find recommendation 




 • Insufficient staff 
• Lack of proper materials 
• Poor reimbursement 
• Increased costs 
• Time constraints 
 
 
The framework of Flottorp et al., is a synthesis of other frameworks and checklists from 
the literature9. The aim of their paper was to compile a comprehensive checklist of 
determinants that could affect physician adherence to clinical guidelines. The result was a 











Table 3. Factors that Prevent or Enable Improvements in Healthcare Professional Practice. Adapted 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The categories identified by Fischer et al. are similar to those of Cabana et al. To develop 
their framework, Fischer et al. conducted a scoping review of the literature.10 Their three 
categories are Personal Factors, Guideline-related Factors, and External Factors. Like 
Cabana et al., they identified physician knowledge and awareness as barriers, however 
they categorized both of these factors under the Personal Factors heading. Beyond 
identifying barriers, they also proposed intervention strategies to combat these barriers. 
The framework has been adapted into a table below.  
 
Table 4. Barriers in Guideline Implementation. Adapted from Fischer et al.10 




• Lack of awareness 
• Lack of familiarity 
• Lack of 
agreement 
• Lack of self-
efficacy  
• Lack of skills  
• Lack of learning 
culture 
• Lack of outcome 
expectancy  
• Lack of 
motivation 
• Lack of evidence 
• Plausibility of 
recommendations 
• Complexity (too 
theoretical) 
• Poor layout 
• Access to guideline 
• Lack of applicability 
• Focus on patients with 
single disease entities 
• Exclusion of patients 
with complex disease 
entities 









• Lack of collaboration  




The framework by Correa et al., differs from the frameworks introduced above in that it 
distinguishes context-dependent barriers and facilitators to guideline adherence 11. In 
contrast to the other four frameworks presented here, Correa et al. explore how 
situational contexts can influence adherence to clinical guidelines. In their paper, the 
 
10 
framework is presented as a chart, alongside several tables of explanations, which have 




Table 5. Barriers and Facilitators to the Implementation of Clinical Practice Guidelines. Adapted 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Barriers to Guideline Adherence in axSpA / AS 
While general guideline adherence is a popular topic in the literature, little is known 
specifically about guideline adherence in axSpA / AS. A literature review on this topic 
has not yet been performed. Given the lack of information in the literature about barriers 
specific to guideline adoption in axSpA / AS, the rheumatologist perspective would be 
critical in discovering which barriers are of the greatest significance. A common 
approach for capturing a variety of perspectives in medical research is via survey. 
Specifically, there are three main types of survey used in medical research, two of which 
we will utilize; “surveys on attitudes to a health service or intervention and 
questionnaires assessing knowledge on a particular issue or topic”.12 The third type, 
epidemiological surveys, will not be used here. Research studies using surveys frequently 
include a focus group during the planning phase. A focus group is a small group of 
people who are recruited to partake in a discussion about a certain topic in order to gather 
data about the topic. Typically, this method of collecting data allows the researcher to tap 
into a deeper understanding of the behaviors and perspectives of the subjects in a way 
that is not as obtainable when using surveys, or one-on-one interviews.13 By utilizing the 
focus group, one can get firsthand insight into the perspectives of the participating 
rheumatologists to develop survey questions which more accurately capture what they 
perceive to be the barriers to guideline adoption.  
 
Objective of the Study 
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The aim of this study is to discover the barriers to guideline adoption for axSpA, as 
perceived by rheumatologists. This includes the following sub-aims: 
• perform a systematic literature review on barriers to guideline adoption in axSpA 
• perform a systematic literature review on online survey deployment methods 
• generate a draft of the survey 
• conduct a focus group with a panel of experts in the field 
• analyze the focus group data  
• finalize survey based on feedback received from the focus group  









Systematic Literature Review (Barriers) 
PubMed and Web of Science were searched using the terms (“guidelines” OR 
“recommendations”) AND (“ankylosing spondylitis” OR “spondyloarthritis”) AND 
(“barrier” OR “adherence” OR “implementation”). Articles published in or before 
November 2020 were considered. Only English language articles available in full text 
were included. The articles were screened for relevance by reading the abstracts and / or 
the full text. Articles were screened out if they were not about the treatment of axSpA, or 
if they were not about or related to guidelines for axSpA. Articles were classified by two 
investigators separately. Any discrepancies in classification were reviewed and resolved 
by consensus.  
 
Systematic Literature Review (Survey Deployment) 
A PubMed search was conducted using the search terms (“email” OR “e-mail” OR 
“social media”) AND (“rheumatologist” AND “survey”). Articles published in or before 
February 2021 were considered. Only English language articles available in full text were 
included. The articles were screened for relevance by reading the abstracts and / or the 
full text. Articles were screened out if they were not primary research including an online 
survey; or if they were not targeted toward physicians who attend to patients with 
rheumatic diseases. Articles were classified by two investigators separately. Any 




Planning the Focus Group 
The focus group was designed to be held virtually over Zoom, with approximately six to 
ten expert participants. An outline of the PowerPoint presentation to be used during the 
focus group was drafted, which included the use of breakout rooms to complete activities 
in smaller groups. The PowerPoint and the corresponding activities were then discussed 
and revised in multiple rounds. Below is the outline presented to focus group participants.  
 
Table 6. Agenda and Timetable for Focus Group. 
Topic Time 
Welcome + Background 5 mins 
Study Introduction 5 mins 
Barrier Brainstorming Exercise 8 mins 
Breakout Exercise 1 15 mins 
Framework Presentation 5 mins 
Breakout Exercise 2 18 mins 
Questionnaire Presentation & Strategy 30 mins 
Wrap-Up 4 mins 
 
 
Conducting the Focus Group 
The focus group took place on Monday March 15th, 2021 via Zoom. Eight participants 
attended including four academic researchers, one rheumatologist in private practice, one 
clinician rheumatologist at an academic medical center, one rheumatology fellow at an 
academic medical center, and one medical student. After a round of brief introductions by 
all participants, a brief summary of the study conducted by Patel et al. was presented via 
PowerPoint, the results of which led to the development of our study. 
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The first activity was a whole-group exercise, and participants were tasked with ranking 
the significance of the barrier to guideline implementation against the importance of the 
recommendation. There were two breakout group exercises, for which the focus group 
was divided into two subgroups. For the first exercise, participants were asked to “devise 
an unsorted list of barriers you perceive to impact the adoption of the guidelines” for the 
specific aspect of the guideline to which they were assigned. Prior to the second exercise, 
the moderators presented a framework devised from articles in the literature. This 
framework, found in Table 7, identified five categories of barriers that impact guideline 
implementation. For the second exercise, the same subgroups were then asked to sort 
their barriers into the categories from the framework presentation, as well as rank the 
significance of these barriers, for example, the most difficult barrier to overcome would 
rank the highest. Group 1 discussed PT and exercise guidelines. Group 2 discussed 
disease activity monitoring guidelines. After the breakout session, the groups came 
together to compare and discuss.  
As a whole group, the participants were asked their opinions on ways to maximize 
response rate for the survey. Additionally, the demographic questions from the drafted 
survey were presented to the whole group for feedback. At the end of the focus group, 
participants were asked to review the drafted survey questions on their own time, and to 
provide feedback on style and content.  
The focus group was recorded with agreement by participants, to remove the distraction 





The initial draft of survey questions found in Supplemental Document 1 were developed 
based on barriers presented in the literature and survey questions from the literature 
found in other questionnaires and surveys. After the conduction of the focus group, the 
expert opinion of the participants informed changes to the survey, leading to the revision 
of the original survey. Question style and content were edited based on feedback from the 
focus group. The revised survey is attached as Supplemental Document 4.  
 
Statistical Analysis  
Excel (Microsoft) was utilized for data extraction and analysis. Calculations including 
mean, median, standard deviation, and ANOVA were performed using statistics tools 







SLR for Barriers to Guideline Adherence 
An SLR was performed of studies which investigated barriers to guideline adherence for 
axSpA or AS. The initial search returned 184 studies after duplications between PubMed 
and Web of Science were removed. One additional article was added from the cited 
sources of an article being screened, thus leaving 185 studies. Further screening excluded 
132 articles, 11 of which were not in English, 91 of which were not related to treatment 
of axSpA / AS, and 30 of which were not related to axSpA / AS guidelines or 
recommendations. The full text of the remaining 53 articles was then assessed for 
eligibility; 12 articles were excluded because they were guideline documents themselves, 
9 were excluded due to being reviews or commentaries, and 10 were excluded on the 





Figure 3. PRISMA Flow Diagram for SLR on Barriers to Guideline Adherence  
 
 
From the 22 primary research articles, the aspect of the recommendation being addressed 
was analyzed. Seven addressed drug therapy; 16 addressed PT or exercise; 2 addressed 
disease activity monitoring; 1 addressed osteoporosis screening or monitoring; and 2 





Figure 4. Aspect of Barriers Covered by Primary Research Studies  
*In some studies, more than one aspect was covered 
 
The method utilized by the 22 primary research articles was also analyzed. Twelve 
articles deployed a survey to patients; 6 deployed a survey to providers; 3 conducted 
patient interviews; 3 conducted provider interviews; 2 conducted an educational 
intervention with providers designed to improve guideline adherence post-intervention; 1 
conducted an educational intervention with patients to determine the role an informative 
handout designed to be given to patients would play in disease outcomes; and 1 




































Figure 5. Research Method Utilized in the Primary Research Articles 
*Some studies used more than one method. 
 
 
It was possible to extract the geographic region where the research studies were 
performed from 20 of the 22 primary research articles. Eighteen of the studies were 
















































On the basis of prior publications, a framework was devised, which was designed to 
synthesize the key factors from each of the frameworks presented above. It was 
determined that five groups of factors were most important when considering barriers to 
guideline adoption: guideline factors, health professional factors, patient factors, practice 
setting factors, and societal factors. Guideline factors are issues with the guidelines 
themselves, such as lack of evidence or clarity, which then pose as barriers to proper 
application. Health professional factors are those that have to do with the provider 
themselves, for example their own familiarity with the guideline, or their motivation to 
follow the guidelines, which then pose as barriers to adherence. Patient factors are those 












serve as barriers to adherence. Practice setting factors include constraints of the practice 
itself, such as the time allowed for each patient visit, or the EMR template for the visit, 
which then pose as barriers to adherence. Lastly, societal factors include barriers beyond 
those specific to a single practice or clinic, such as access to healthcare and the 
accompanying costs, which all pose as barriers to adherence. The table outlining these 
factors, as well as which studies highlighted their importance, can be found below. 
 
Table 7. Synthesis of Barriers. Adapted from Frameworks in the Literature as well as Expert Opinion 
from the Focus Group.  
 Cabana Francke Flottorp Correa Fischer 
Guideline Factors  
e.g., clarity, support of 
scientific evidence 
x x x x x 
Health Professional* Factors  
e.g., awareness, knowledge, 
intrinsic motivation, length of 
time in practice 
x x x x x 
Patient Factors  
e.g., patient preferences, 
knowledge, intrinsic 
motivation, comorbidities 
x x x x x 
Practice Setting Factors  
e.g., routine of current practice, 
ease of interactions between 
health professionals, local 
implementation strategies, 
EMR 
x x x  x 
Societal Factors  
e.g., extrinsic incentives, 
payment, access to health care  
  x x x 
*Health Professional refers to any healthcare provider involved in the care of the patient in the clinic  
 
As a visual aid to further explain the factors from the above table, the following schema 
was also created and presented to the focus group. The schema is designed to show that 
health professional factors and patient factors can influence each other. Furthermore, the 
guideline factors and practice setting factors can also influence health professional factors 
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and patient factors. Societal factors are not immediately at play in guideline adherence; 




Figure 7. Schema of Factors Influencing Guideline Adoption. Visual representation of Table 7.  
 
From these five categories, we then created a draft survey, which can be found in full in 
the Appendix of this paper, as Supplementary Document 1. The survey was designed to 
cover the five groups of factors mentioned above, as well as basic demographic 
information about the respondents. The number of questions that target each category are 









Table 8. Breakdown of Survey Question Categories.  
Health Professional Factors 4 questions 
Patient Factors 5 questions 
Societal Factors 1 question 
Guideline Factors 4 questions 
Practice Setting Factors 14 questions 
Demographics 5 questions 
 
SLR for Survey Deployment Strategy 
A second SLR was performed of studies which deployed online surveys targeting 
physicians who attend to patients with rheumatic diseases. The initial PubMed search 
returned 86 studies. Screening excluded 34 studies; 3 of which were not in English, 2 
were not full text articles, 12 did not involve the use of an online survey, and 17 were not 
targeted to physicians who attend to patients with rheumatic diseases leaving 52 studies 




Figure 8. PRISMA Flow Diagram for SLR on Survey Deployment  
 
 
Of the 52 studies included in the analysis, 40 studies included sufficient data to calculate 
a participant response rate. The mean response rate was 0.33 with a standard deviation of 
0.22. The median response rate was 0.27 with a range from 0.04 to 0.78. 
Forty-eight studies included information on the number of times physicians were 
contacted to participate. Of those, 24 studies contacted physicians only once, 15 studies 





Figure 9. Number of Studies that Contacted Physicians Once, Twice, or Three or More Times. 
 
Thirty-eight of the 40 studies that included enough information to calculate response rate 
also provided information on the number of times participants were contacted. For the 16 
studies that only contacted physicians once the mean response rate was 0.39 with a 
standard deviation of 0.26. For the 14 of these studies that contacted physicians twice, the 
average response rate was 0.23 with a standard deviation of 0.2. For the 8 studies that 
contacted physicians three or more times, the average response rate was 0.39 with a 
standard deviation of 0.23. There was no statistically significant difference in response 


























Figure 10. Comparison of Response Rate to the Number of Times Physicians were Contacted to Participate 
 
Fifty studies included information about how participants were contacted and how they 
received the survey. Thirty-nine studies used email alone to contact physicians, 1 study 
used only social media, and 10 studies used both social media and email. Types of social 
media used included Twitter, Facebook, Instagram, LinkedIn, Study-Specific Websites, 
Online Newsletters, ResearchGate, and WhatsApp.  
Forty-nine of the 52 studies provided information on where potential participants were 
recruited from. Thirty-two studies recruited from national rheumatology or medical 
organizations, 17 recruited from international rheumatology or medical organizations, 7 
recruited from regional rheumatology or medical organizations, and 7 used non-
organization-based recruitment methods. The non-organization-based recruitment 




























distribution of unique emails to contacts, surveys forwarded to colleagues, 
rheumatologists nominated by members of steering committees, the social media 
platforms of a Rheumatology journal, a search through the websites of health insurance 
companies, and general social media posts.  
Forty-six studies included the geographic location where the research was conducted. 
Thirty-two studies were conducted within one country, while 14 studies were multi-
national.  
Only seven studies included information on the approximate time it would take to 
complete their survey. This time frame ranged from 3 minutes to 20 minutes, with a 
median time of 7 minutes. 
Thirty-eight studies included enough information to calculate response rate while also 
providing information on if the study was multinational. The average response rate for 
the 27 studies conducted in one country was 0.30 with a standard deviation of 0.23, while 









Focus Group Whole Group Activity 
For the initial group exercise, the participants were presented with the graph shown 
below and asked to suggest placement of the major guideline categories: 
pharmacotherapy, physical therapy & exercise, other non-pharmacological therapies, 
disease activity monitoring, counseling and education, and management of comorbidities. 
In this matrix, the x axis represents the importance of the recommendations, while the y 


























Figure 12. Group Exercise Slide on Barrier Height versus Importance of Recommendation.  
 
 
The initial full group exercise was designed to be presented as a graph, but due to 
differing opinions among participants, the results will instead be presented as quotes or as 
summarized points. The first participant stated that “aside from pharmacotherapy, 
everything on this list has barriers”. This participant went on to say that since 
pharmacotherapy is so effective these days, the other aspects of treatment are not as 
relevant. Furthermore, this participant indicated that disease activity monitoring is not 
done in other disease types beyond just axSpA / AS, so it is not a problem unique to this 
disease population. Another participant elaborated on pharmacotherapy, indicating that 
there is a different barrier that exists which is the knowledge of which step to take next, 
i.e. if one type isn’t working. One moderator took the point further, asking “considering 
that so few physicians get disease activity monitoring measures is that because they are 
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simply further to the left on this scale?” A different participant chimed in to say that they 
always get a RAPID3 on every patient which is facilitated by the workflow in the clinic; 
each patient completes a questionnaire in the waiting room before even coming into the 
exam room. This participant found this to be especially useful in informing conversations 
with their patients and would stand by the importance of disease activity monitoring 
measures. This participant added that this approach is useful because it does not take up 
time during the actual visit, since it is filled out by the patient beforehand, and that not 
spending time on these measures during the visit itself is critical given the small window 
of time allotted to follow-up visits. This same participant stated that “counseling and 
education tend to fall by the wayside”, typically because physicians have an agenda when 
they walk into visits (all of the steps they need to complete for the visit at hand), that 
having a true conversation with the patient gets pushed to the side. There was general 
agreement among participants that this aspect had the highest barrier, simply because of 
all the things that need to happen during a visit (labs, prior authorizations, reviewing 
results, ordering tests etc.). Another participant chimed in that a major concern with many 
of the aspects of care was that things were being done for remuneration purposes only 
instead of being done in a meaningful way. Oftentimes having patients fill things out in 
the waiting room can be used to increase complexity level of the visit, and therefore bill 
at a higher rate. Another issue was brought up regarding counseling and education, that 
oftentimes patients don’t understand the goals of therapy because there is a lack of 
communication with their doctor. This was presented as a huge barrier, because the 
patient does not know how they are doing even though they may be doing well clinically, 
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because there is a disconnect with what the objectives are and how the patient feels, or 
how the patient thinks they should be doing.  
 
Focus Group Breakout Group Activities 
The goal of the first breakout group activity was to get participants thinking about 
barriers to the specific aspect they were assigned, either PT / exercise or disease activity 
monitoring. The second breakout group activity was designed to take this a step further. 
Prior to the second breakout group, the framework from Table 7 was presented by the 
moderators. The goal of the framework presentation was two-fold; first it was to 
demonstrate what the literature had provided as a basis for factors that affect guideline 
adoption in axSpA / AS and leave room for the participants to make edits, second the 
next breakout group activity was designed based on the presented framework. 
Participants were asked to sort the barriers they came up with in activity one into 1 of the 
5 categories of factors from the framework, as well as rank the importance of each of the 
barriers within these categories. The resultant table for each group can be found below. A 
specific comment was made about societal factors, because one of the moderators 
brought up the fact that in other countries, prescription of biologics is tied to disease 
activity measurements. One participant said that if that were the case here, there was no 
doubt that more doctors would do disease activity measurements. Another participant 
said that since it isn’t the case here, a different incentive would be money. Another 
participant said, “I guess we just have to believe that treat-to-target actually works, and I 
don’t know that everyone does.” 
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Table 9. Group 1 Breakout Exercise from Focus Group. Barriers to adherence to disease activity 
monitoring guidelines in axSpA / AS ranked by importance.  
 Disease Activity Monitoring 
Guideline Factors 1. Specificity of inflammatory markers for rheumatic disease versus other 
causes (e.g., a virus) 
2. Justification of when to use and why (convincing providers and 
demonstrating efficacy) 
3. In what clinical context are they most effective (e.g., all of the time, 
certain scenarios, certain patients) 
Health Professional 
Factors 
1. Education (especially for new rheumatologists) 
a. How to use 
b. How to collect / document 
Patient Factors 1. Stress on the patient by collecting more measures 
a. need to explain what they are 
b. what impact they have on their care 
c. how / if it affects the outcome / prognosis 
2. Increased number of lab draws could be burdensome 
Practice Setting Factors 1. Technology behind collecting and documenting the disease measures 
2. Acceptance by IT infrastructure / administration (e.g., incorporating 
them into the OMR) 
3. Challenge of lab test interpretation 
4. Sharing results / communication regarding abnormal results  
Societal Factors 1. Loss of physician autonomy / the art of medicine 
2. Cultural factors (e.g., a patient who believes that he / she only has a 














Table 10. Group 2 Breakout Exercise from Focus Group. Barriers to adherence to PT / exercise 
guidelines in axSpA / AS ranked by importance. 
 Exercise / Physical Therapy 
Guideline Factors 1. Guidelines are vague 
a. No subsets / stratification 
b. No specifics of PT 
2. Guidelines are hard to understand 
Health Professional 
Factors 
1. Don’t understand what PT entails 
2. Belief that PT / exercise is less effective than pharmacologic therapy 
3. Don’t know how to write a good prescription for PT 
4. Inability to convince patients to exercise 
5. Unaware of guidelines 
Patient Factors 1. Cost of PT 
2. Unable to get time off work for PT 
3. Don’t think it works  
4. Would rather have medicine because the time and effort involved is less 
than that required for PT / exercise 
5. Physical distance to location offering PT is too far 
Practice Setting Factors 1. In-Network versus Out-Of-Network 
a.  Large group practices (where their insurance accepted) may 
discourage / prevent patients from going to a more convenient 
location (where their insurance is not accepted) 
2. Most PT clinics do not have PT tailored to inflammatory arthritis 
Societal Factors 1. The Pandemic 
2. External, structural factors (e.g., race, culture) that impact patient level 
factors 
3. Access in the US 
4. Belief that pharmacologic therapy is better than nonpharmacologic 
therapy (a US issue) 
 
A particularly interesting point came up when the groups reconvened, which was that one 
participant said patients always ask what else they can do for their disease besides taking 
drugs. This participant asked how everyone else would answer that question. One 
participant said they would admit to their bias and say that pharmacotherapy is the best 
way. Another participant said patients want to know what the “anti-inflammatory diet” is, 
but that when the topic of exercise comes up, patients give a bunch of reasons for why 
they cannot do that. Another participant exclaimed “everyone wants a diet but not 
exercise”. There seemed to be consensus that the idea of fad diets and not exercising 
might be “an American thing”. Another participant noted that the idea that you can 
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change your health significantly with your diet is very unique to the United States. There 
seemed to be consensus that the barrier to PT might be lower in other countries, because 
PT is more accessible and widely available in other countries than in the US. One 
participant shared that patients often say that in other countries it is easy for patients to 
get PT at their houses, or get massages, whereas in the US you need to go through 
referrals, and get prescriptions, and it is much more difficult to navigate. Another 
participant notes that PT preceded pharmacotherapy in Europe, which could be a reason 
for the high accessibility there compared with the US.  
 
Focus Group Feedback on Response Rate and Survey Questions 
The participants were then asked their opinion on methods to maximize the response rate 
once the survey was deployed. Several areas were highlighted, including survey length, 
email subject line, and number of invitation / reminder emails to send. There was also the 
question of incentives. The literature indicated the survey should be between 10-15 
minutes maximum, which the focus group participants agreed with. One participant said 
that an important factor would be number of questions per page, i.e., not just continuous 
scrolling. Being able to see completion status would be helpful. The participants also said 
that having a subject line that clearly indicated that this was academic research being 
done by a student would make target participants more likely to respond. Our research 
from the literature showed no correlation between response rate and number of times 
participants were contacted, and focus group participants generally agreed, suggesting 
“one email and maybe one reminder”. The topic of social media was also brought up, 
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with one participant in particularly in favor of this route. The other participants were in 
agreement that using social media would be an excellent way to target a larger group of 
potential participants. Possible methods of social media deployment were also discussed, 
such as Twitter, LinkedIn, Doximity, and a secret Facebook group mentioned by one 
participant. The idea that the ACR might broadcast the survey was also suggested. When 
the question arose of whether or not this might result in the recruitment of non-
rheumatologist and / or non-US physician respondents, one participant suggested a 
specific screening question, i.e., “are you a rheumatologist practicing in the US” to 
remedy this issue. If no were selected as an answer to the preliminary question, the 
survey would close. The idea of geographic region was also discussed, however one 
participant stated that with REDCap it is possible to stratify responses by region, such 
that any regional differences or biases could also be seen. It was also noted that the larger 
the pool of potential participants reached, the larger number of responses would be 
received, especially considering the low expected response rate as noted in the literature. 
One of the moderators brought up the concern of introducing bias when using social 
media, i.e., an age determined preference for using social media versus not. A participant 
responded that bias would be a factor no matter what, and that targeting participants in as 
many ways as possible would be the best way to limit that bias. Given that the primary 
interest was to have broad coverage of many practice settings, one participant suggests 
getting buy-in from larger groups to help disseminate. Another participant recapped 
“you’re better off with the largest possible number of participants and the shortest 
possible survey”.  
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The demographic questions were then presented to the participants, with a focus on the 
question asking how many axSpA / AS patients are seen per week. This prompted one 
participant to note that if focus group participants were to answer that question 
themselves, their number would be quite small, even though a large proportion of their 
patients had axSpA or AS, simply because they are an academic researcher and do not 
see many patients in general. To better capture the purpose of the question, one 
participant suggested “what is the primary focus of your practice as a rheumatologist” 
with options of all rheumatology cases without restriction, emphasis on spondyloarthritis, 
emphasis on lupus or similar autoimmune disorders, mostly osteoarthritis and 
fibromyalgia, or emphasis on RA. Since the purpose of this question was to gauge the 
axSpA / AS expertise of the answering physician, the proposed wording would capture 
just that.  
At the end of the focus group, participants were asked if they would review and comment 
on all the questions drafted thus far for the survey. Participants were asked to do this on 
their own time, and to send their responses back so that the investigators could edit the 
survey accordingly. The revised survey can be found in full in the Appendix of this 
paper, Supplementary Document 4. Changes made from the original draft of the survey 








The results have shown that little research has been done to investigate barriers to 
guideline adoption for axSpA / AS. Only 1 of the 22 studies identified in the SLR was 
conducted in the US, demonstrating the need for further research in the US. Furthermore, 
almost all of the studies identified focused on drug therapy or PT / exercise. The SLR on 
survey deployment methods identified 52 articles, 40 of which included sufficient 
information to calculate response rates. The mean response rate for electronic surveys 
distributed to rheumatologists was 0.33; there was no statistically significant difference in 
response rate for studies which contacted physicians once, twice, or three or more times. 
From the available literature, a framework was synthesized, that captures 5 major 
categories of barriers to guidelines adherence: guideline factors, health professional 
factors, patient factors, practice setting factors, and societal factors. A survey was drafted, 
with questions targeting each of the 5 categories included in the framework. Suggestions 
from the expert participants of the focus group resulted in a revised survey consisting of 
33 questions. From the literature we were able to analyze methods used to recruit survey 
participants, as well as strategies to improve response rate for electronic survey 
deployment. Additionally, the focus group proposed ideas for survey dissemination, 
including strong support for the utilization of social media in addition to email 
invitations.  
Dearth of Literature on Barriers in axSpA / AS 
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In the research that has been conducted on barriers to guideline adoption in axSpA / AS, 
there tends to be a focus on the pharmacologic and PT / exercise components of the 
guidelines. In contrast, very few studies have investigated barriers to the adoption of 
guidelines for disease activity monitoring, osteoporosis screening, and other non-
pharmacologic treatments. There is also a large discrepancy in the number of studies that 
conducted research on barriers in Europe compared to those conducted in the US. Since 
the healthcare system of the US is different than those in Europe, it is possible that the 
results of the European studies, and their proposed solutions, would neither be relevant 
nor feasible in the US. This indicates a need for more studies investigating barriers 
specific to physicians and patients within the US healthcare system.  
 
Strategies to Maximize Response Rate for Electronic Surveys 
The results of our study indicate that there was no benefit to contacting participants more 
than once, since the response rate for studies in which physicians were contacted was the 
same as for studies in which physicians were contacted 3 or more times. The focus group 
participants agreed with the premise that the majority of responses will be received after 
the initial invitation is sent out, and that one follow-up is all that should be done.  
It is also worth noting that the calculated average response rate of 0.3 for electronic 
survey deployment had a very wide standard deviation of 0.22. Thus, there are likely 
other factors attributing to response rate beyond those addressed in our analysis. One of 
these factors may be how important the physician perceives the survey to be. If he or she 
believes the topic of the survey is worth studying, it is more likely that he or she would 
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respond. This was emphasized by focus group participants, who agreed that a targeted 
participant would be more likely to respond to a survey if they knew they were helping 
someone, i.e., a student conducting research.  
 
Strengths and Limitations 
One of the major strengths of this study was the use of expert opinions in the 
development and refinement of survey questions. By utilizing experts in the field of 
axSpA / AS for the focus group, it was possible to capture the perspective of the target 
audience for the survey. Another strength of the study is that since barriers to guideline 
adoption for axSpA have not been widely studied, this study may bring more attention to 
gaps between the intention of the guideline and the actual implementation of the 
guideline in medical practices.  
A major limitation is that we were not able to distribute the survey to the target group of 
rheumatologists due to time constraints. Therefore, we have no results for the survey 
questions. Another potential weakness of the study is the limited size of the focus group. 
Having a smaller group may mean that the feedback we received is not representative of 
all perspectives of rheumatologists. Therefore, the barriers signified as most important 
from above may not accurately reflect the perspective of the overall population of 





The SLR conducted to identify barriers to guideline adherence in axSpA / AS 
demonstrated a dearth of information specific for this disease entity, indicating a need for 
further research. The focus group provided firsthand perspective, allowing for 
modification of the survey to capture the most informative data. Furthermore, the focus 
group provided insight into survey dissemination methods and ideas to maximize the 




Supplementary Document 1: Draft of Survey Prior to Conduction of Focus Group 
 
Section A: Clinical Scenario (Health Professional Factors) 
 
1. A 32-year-old male with axial spondyloarthritis (diagnosis 5 years ago, HLA-B27 
positive, unequivocal findings of sacroiliitis on pelvic radiographs) returns for routine 
f / u. He has no extraspinal disease manifestations and no other medical problems. His 
disease-related symptoms have been well controlled with a TNF inhibitor. Please 
describe what you would do for this patient in your clinical practice. Select all that 
apply. 
• Assess disease activity in qualitative terms (e.g., excellent, good, stable, 
better, worse) 
• Measure disease activity using a validated questionnaire (e.g., BASDAI) 
• Review vaccination record. 
• Review smoking status. 
• Perform a physical examination including peripheral joints and spine. 
• Record spinal mobility measurements (e.g., Schober, occiput to wall distance) 
• Discuss exercise and recommend physical therapy 
• Order CRP and / or ESR. 
• Order spinal radiographs (if not performed during the last 2-5 years) 
• Other: write in box 
 
2. The patient is doing well. His disease has been well controlled. He rarely takes 
Ibuprofen. He has been on a stable dose of the TNF inhibitor for 5 years. Which 
management approach would you choose? Select your single best answer. 
o Keep on same dose of TNF inhibitor, f / u in 3-6 months 
o Keep on same dose of TNF inhibitor, f / u in 1 year 
o Discuss and Implement dose reduction of the TNF inhibitor, f / u in 3-6 
months 
o Recommend discontinuation of the TNF inhibitor, f / u in 3-6 months 
 
3. Under which circumstances do you order a DXA scan for patients with axial 
spondyloarthritis? Select all that apply. 
• All Women with AS above age 40 
• All patients with AS at least once 
• Every 5 years after the diagnosis of AS 
• History of spine fracture or recent non-spinal fracture  
• X-ray reports commenting on low bone density 







4. Which of the following disease scores have utility to measure disease activity in 
patients with axial SpA / AS? 
 















axSpA / AS 
Don’t 
know it 
ASDAS       
BASDAI       
CDAI       
DAS28       
RAPID3       
 
Section B: Patient and Societal Factors 
 
Patient Factors 
5. Do you provide any patient facing handouts regarding guidelines to treatment at clinic 
visits? 
o Yes  
o No 
 
6. Using the scale below, approximately what percentage of the axSpA / AS patients in 
your clinic come prepared with knowledge of the guidelines? Select the best answer. 
 
None 25% 50% 75% 100% 
     
 
7. Approximately what percentage of your patients with axSpA / AS do regular 
strengthening exercises and or stretching on their own at home? Select the best 
answer.  
 
None 25% 50% 75% 100% 
     
 
8. Approximately what percentage of your patients with axSpA / AS engaged in 
organized PT over the past year? Select the best answer.  
 
None 25% 50% 75% 100% 







9. What barriers do you perceive that prevent your patients from exercising to the 




• Lack of Awareness of recommendation  
• Other: write in box 
 
Societal Factors 
10. In your opinion, should the prescription of biologics be linked to specific thresholds 






Section C: Guideline Factors 
 
11. Which resources do you consult for the questions regarding the management of 
patients with axSpA / AS (choose all that apply)?  
• ACR / SAA / SPARTAN guidelines 
• ASAS guidelines 
• Up-to-Date 
• Pubmed 
• Textbooks (e-books or hardcopy) 
• Other: write in box 
 
12. For which aspects of the management of axSpA / AS patients do you reference 
guidelines (choose all that apply)? 
• Pharmacological therapy 
• Disease activity monitoring 
• Physical therapy / exercise 
• Osteoporosis screening / management 
• Diet and lifestyle 
• Vaccination 










13. How did you learn about the ACR / SAA / SPARTAN guidelines (choose all that 
apply)? 
• Arthritis & Rheumatology publication 
• Arthritis Care & Research publication 
• ACR Annual Meeting 
• The Rheumatologist 
• Online source, e.g., Rheum Now 
• Educational seminars or conferences, e.g., SPARTAN-GRAPPA symposia 
• Social media, e.g., Twitter 
• Other: write-in box 
 

















     
User 
Friendliness 
     
 
 
Section D: Practice Setting Factors 
 
15. Do you routinely collect patient-reported data using patient facing tablets / electronic 




16. Which electronic medical record system does your clinic / institution use? 













17. Does your EMR have templates for disease activity monitoring (e.g., BASDAI)? 
o Yes 
o No 
o Don’t know 
 
18. Does your EMR provide handouts or other educational material for patients with 
axSpA / AS that can be printed out or sent electronically? 
o Yes 
o No 
o Don’t know 
 
19. Please rate the ease of application of the following aspects of the guidelines in your 













     
Physical 
Therapy  
     
 
20. Please rank the following barriers to implementing guidelines in order, with the top of 
the list being the most significant? Please drag and drop the items from the left hand 
side into the box on the right hand side.  
 
21. If there are any barriers you observe in your practice that were not on the list, please 
include them here: 
o Write in box 
 





23. Are the disease activity monitoring assessments completed by you (the physician) or 
by another healthcare provider? 
o Me 







24. If the disease activity monitoring assessments are completed by someone else, what is 





• Other: write in box 
 
25. If you find that time is a barrier – is this true for all clinic visits or specifically your 
AS patients? 
o All visits 
o Just AS patient visits 
 
26. Is there a specific implementation plan for the AS guidelines within your practice 




27. [If above answer was yes] what is it? 
o Write in box 
 
28. If you advise a patient to engage in back exercises at home, what kind of resources do 
you provide this patient to guide them? 
o Printed Handout 
o Website Resource Link 
o Other: write in box 
 
 
Section E: Demographic Questions 
 
29. What gender do you identify with? 
o Male 
o Female 
o Prefer not to disclose 
o Prefer to self-describe: write in box 
 
30. What is your level of training? 
o Board-certified rheumatologist 
o Rheumatology fellow 
o Physician assistant or nurse practitioner 





31. [If Board-certified rheumatologist selected]: Year you completed your rheumatology 
subspecialty training? 
o drop down menu 
[If Rheumatology fellow selected]: Year you started fellowship training 
o drop-down menu 
[If PA, NP or Other]: skip 
 
32. Select the option that best describes the setting in which you practice: 
o Academic Medical Center 
o Hospital-based practice 
o Group practice 
o Solo practice 
o Retired 
o Other: write-in box 
 
33. On average, how many axSpA / AS patients do you see per week? 
o < 5 
o 5 - 10 
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Supplementary Document 4: Revised Survey Post Conduction of Focus Group 
*Note that changes made from the draft survey from Supplementary Document 1 are 
italicized.  
 
Section A: Clinical Scenario (Health Professional Factors) 
 
1. A 32-year-old male with axial spondyloarthritis (diagnosis 5 years ago, HLA-B27 
positive, unequivocal findings of structural damage in the sacroiliac joints) returns 
for routine f / u. He has no extraspinal disease manifestations and no other medical 
problems. His disease-related symptoms have been well controlled with a TNF 
inhibitor. Please describe what you would do for this patient in your clinical practice. 
Select all that apply. 
• Assess disease activity in qualitative terms (e.g., excellent, good, stable, 
better, worse) 
• Measure disease activity using a validated questionnaire (e.g., BASDAI, 
ASDAS) 
• Review and discuss vaccination record. 
• Review and discuss smoking status. 
• Perform a physical examination including peripheral joints and spine. 
• Record spinal mobility measurements (e.g., Schober, occiput to wall distance) 
• Discuss exercise and recommend physical therapy 
• Order CRP and / or ESR and / or CBC and / or BMP / CMP. 
• Order spinal radiographs (if not performed during the last 2-5 years) 
• Other: write in box 
 
2. The patient is doing well. His disease has been well controlled. He rarely takes 
Ibuprofen. He has been on a stable dose of the TNF inhibitor for 5 years. The patient 
asks for your recommendation; which management approach would you choose? 
Select your single best answer. 
o Keep on same dose of TNF inhibitor, f / u in 3-6 months 
o Keep on same dose of TNF inhibitor, f / u in 1 year 
o Discuss and Implement dose reduction of the TNF inhibitor, f / u in 3-6 
months 
o Recommend discontinuation of the TNF inhibitor, f / u in 3-6 months 
 
3. Under which circumstances do you order a DXA scan for patients with axial 
spondyloarthritis. Select all that apply. 
• All Women with AS above age 40 
• All patients with AS at least once 
• Every 5 years after the diagnosis of AS 
• History of spine fracture or recent non-spinal fracture  
• X-ray reports commenting on low bone density 
• Family history of osteoporosis 
• History of long-term steroid / glucocorticoid use 
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• Other: write in box 
4. In your opinion, which of the following disease scores have utility to measure disease 
activity in patients with axial SpA / AS? 
 















axSpA / AS 
Don’t 
know it 
ASDAS       
BASDAI       
CDAI       
DAS28       
RAPID3       
 
Section B: Patient and Societal Factors 
 
Patient Factors 
5. Do you provide any patient facing handouts regarding guidelines to treatment at clinic 
visits? 
o Yes  
o No 
 
6. Using the scale below, approximately what percentage of the axSpA / AS patients in 
your clinic come prepared with knowledge of specific guideline recommendations? 
Select the best answer. 
 
None 25% 50% 75% 100% 
     
 
7. Approximately what percentage of your patients with axSpA / AS do regular 
strengthening exercises and or stretching on their own at home? Select the best 
answer.  
 
None 25% 50% 75% 100% 
     
 
8. Approximately what percentage of your patients with axSpA / AS engaged in 
organized PT over the past year? Select the best answer.  
 
None 25% 50% 75% 100% 






9. What barriers do you perceive that prevent your patients from exercising to the 








10. In your opinion, should the prescription of biologics be linked to specific thresholds 







Section C: Guideline Factors 
 
11. Which resources do you consult for the questions regarding the management of 
patients with axSpA / AS (choose all that apply)?  
• ACR / SAA / SPARTAN guidelines / corresponding website 
• ASAS guidelines / corresponding website 
• Up-to-Date 
• Pubmed 
• Textbooks (e-books or hardcopy) 
• Colleagues 
• Other: write in box 
 
12. For which aspects of the management of axSpA / AS patients do you reference 
guidelines when considering these management options (choose all that apply)? 
• Pharmacological therapy 
• Disease activity monitoring 
• Physical therapy / exercise 
• Osteoporosis screening / management 
• Diet and lifestyle 
• Vaccination 








13. How did you learn about the ACR / SAA / SPARTAN guidelines (choose all that 
apply)? 
• Arthritis & Rheumatology publication 
• Arthritis Care & Research publication 
• ACR Annual Meeting 
• The Rheumatologist 
• Online source, e.g., Rheum Now, EBRheum, Rheuminations 
• Educational seminars or conferences, e.g., SPARTAN-GRAPPA symposia 
• Social media, e.g., Twitter 
• Other: write-in box 
 

















     
User 
Friendliness 




Section D: Practice Setting Factors 
 
15. Do you routinely collect patient-reported data (i.e., RAPID3) using patient facing 




16. Which electronic medical record system does your clinic / institution use? 












17. Does your EMR have templates for disease activity monitoring (e.g., BASDAI)? 
o Yes 
o No 
o Don’t know 
 
18. Does your EMR provide handouts or other educational material for patients with 
axSpA / AS that can be printed out or sent electronically? 
o Yes 
o No 
o Don’t know 
 
19. Please rate the ease of application of the following aspects of the guidelines in your 













     
Physical 
Therapy  
     
 
20. Please rank the following barriers to implementing guidelines in order, with the top of 
the list being the most significant? Please drag and drop the items from the left hand 
side into the box on the right hand side.  
 
21. If there are any barriers you observe in your practice that were not on the list, please 
include them here: 
o Write in box 
 





23. Are the disease activity monitoring assessments completed by you (the physician) or 
by another healthcare provider? 
o Me 







24. If the disease activity monitoring assessments are completed by someone else, what is 






• Other: write in box 
 
25. If you find that time is a barrier – is this true for all clinic visits or specifically your 
AS patients? 
o All visits 
o Just AS patient visits 
 
26. Is there a specific implementation plan for the AS guidelines within your practice 




27. [If above answer was yes] what is it? 
o Write in box 
 
28. If you advise a patient to engage in back exercises at home, what kind of resources do 
you provide this patient to guide them? 
o Printed Handout 
o Website Resource Link 
o Other: write in box 
 
 
Section E: Demographic Questions 
 
29. What gender do you identify with? 
o Male 
o Female 
o Prefer not to disclose 
o Prefer to self-describe: write in box 
 
30. What is your level of training? 
o Board-certified rheumatologist, practicing 
o Board certified rheumatologist, retired 
o Rheumatology fellow 
o Physician Assistant or Nurse Practitioner 




31. [If Board-certified rheumatologist selected]: Year you completed your rheumatology 
subspecialty training? 
o drop down menu 
[If Rheumatology fellow selected]: Year you started fellowship training 
o drop-down menu 
[If PA, NP or Other]: skip 
 
32. Select the option that best describes the setting in which you practice: 
o Academic Medical Center 
o Hospital-based practice 
o Group practice 
o Solo practice 
o Retired 
o Other: write-in box 
 
33. What is your primary practice focus as a Rheumatologist? 
o All rheumatology cases, no restrictions 
o Emphasis on Spondyloarthritis 
o Emphasis on Lupus and similar autoimmune diseases 
o Emphasis on RA primarily 
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